A Multicentre Double-blind, Placebo-controlled, Randomised, Parallel-group Study to Evaluate the Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer's Disease.

Trial Profile

A Multicentre Double-blind, Placebo-controlled, Randomised, Parallel-group Study to Evaluate the Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer's Disease.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2016

At a glance

  • Drugs Lornoxicam (Primary)
  • Indications Alzheimer's disease
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 01 Jun 2012 Additional trial locations added as reported by European Clinical Trials Database.
    • 01 Jun 2012 Company added in association field as reported by European Clinical Trials Database.
    • 31 Mar 2012 This trial has been recruiting in Slovakia, completed in Germany and; discontinued in Czech Republic and Austria as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top